A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOGG1303, DOENCA trial

Journal of Gynecologic Oncology ◽

10.3802/jgo.2021.32.e64 ◽

2021 ◽

Vol 32 ◽

Author(s):

Kensuke Hori ◽

Shin Nishio ◽

Kimio Ushijima ◽

Yuka Kasamatsu ◽

Eiji Kondo ◽

...

Keyword(s):

Endometrial Cancer ◽

Cancer Treatment ◽

Phase Ii ◽

Uterine Endometrial Cancer ◽

Download Full-text

Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0034-1388557 ◽

2014 ◽

Vol 74 (S 01) ◽

Author(s):

F Hilpert ◽

C Kurzeder ◽

B Schmalfeldt ◽

P Neuser ◽

N de Gregorio ◽

...

Keyword(s):

Ovarian Cancer ◽

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Multicenter Phase ◽

Platinum Resistant ◽

Recurrent Endometrial Cancer

Download Full-text

PHASE II STUDY OF CARBOPLATIN PLUS DOSE DENSE PACLITAXEL BEFORE AND AFTER RADICAL HYSTERECTOMY FOR LOCALLY ADVANCED CERVICAL CANCER (SANKAI GYNECOLOGIC STUDY GROUP 016 STUDY).

10.26226/morressier.597eedbed462b80296ca0a3d ◽

2017 ◽

Author(s):

Nagao Shoji

Keyword(s):

Cervical Cancer ◽

Phase Ii ◽

Radical Hysterectomy ◽

Phase Ii Study ◽

Locally Advanced ◽

Study Group ◽

Advanced Cervical Cancer ◽

Locally Advanced Cervical Cancer ◽

Before And After ◽

Download Full-text

EVALUATION OF THE QUALITY OF CARE (QOC) OF UTERINE CANCER IN BELGIUM - EFFECTIVENESS OF ENDOMETRIAL CANCER TREATMENT (EFFECT) PROJECT

10.26226/morressier.599bdc7ad462b80296ca107f ◽

2017 ◽

Author(s):

Nancy Van Damme

Keyword(s):

Endometrial Cancer ◽

Quality Of Care ◽

Cancer Treatment ◽

Treatment Effect ◽

Download Full-text

A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04224922 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Stage Ii ◽

Weekly Paclitaxel ◽

Download Full-text

Faculty Opinions recommendation of Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1122997.580108 ◽

2008 ◽

Author(s):

Maurie Markman

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Download Full-text

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718551258.793527270 ◽

2017 ◽

Author(s):

Paola Gehrig

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Download Full-text

Faculty Opinions recommendation of A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.722006345.793527263 ◽

2017 ◽

Author(s):

Paola Gehrig

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Download Full-text

Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.194 ◽

2015 ◽

Vol 137 ◽

pp. 79

Author(s):

N.D. Fleming ◽

R.L. Coleman ◽

C.S. Tung ◽

M.F. Munsell ◽

A.K. Sood

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Current opinion on bevacizumab on endometrial cancer treatment

Expert Opinion on Biological Therapy ◽

10.1517/14712598.2015.995624 ◽

2014 ◽

Vol 15 (2) ◽

pp. 299-307 ◽

Author(s):

Stefano Bogliolo ◽

Chiara Cassani ◽

Barbara Gardella ◽

Valentina Musacchi ◽

Luciana Babilonti ◽

...

Keyword(s):

Endometrial Cancer ◽

Cancer Treatment ◽

Current Opinion

Download Full-text